CRNX

SEC source: 0001209191-21-048375 · doc4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-047402 · doc4.xml · derivative · entry 3

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,092

Underlying: Common stock · 5,000 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-047402 · doc4.xml · nonDerivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,536

F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.50. The range of sales prices on the transaction date was $19.50 to $19.52 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001209191-21-047402 · doc4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-046554 · doc4.xml · derivative · entry 3

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,092

Underlying: Common stock · 5,000 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-046554 · doc4.xml · nonDerivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,536

F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.71. The range of sales prices on the transaction date was $20.54 to $21.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001209191-21-046554 · doc4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-042769 · doc4.xml · derivative · entry 1

WIERENGA WENDALL · CIK 0001235945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-21

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-21-042768 · doc4.xml · derivative · entry 1

Nichols Weston · CIK 0001746376 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-21

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-21-042767 · doc4.xml · derivative · entry 1

Okey Stephanie · CIK 0001742616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-21

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-21-042766 · doc4.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-21

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-21-042765 · doc4.xml · derivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-21

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-007202 · doc5.xml · nonDerivative · entry 1

Wilson Marc · CIK 0001702265 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,281

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).

SEC source: 0000899243-21-015456 · doc4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,963,517

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-21-016278 · doc4.xml · derivative · entry 1

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,000

Underlying: Common Stock · 131,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.

SEC source: 0001209191-21-016245 · doc4.xml · derivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,000

Underlying: Common Stock · 294,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.

SEC source: 0001209191-21-016288 · doc4.xml · derivative · entry 1

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.

SEC source: 0001209191-21-016263 · doc4.xml · derivative · entry 1

Wilson Marc · CIK 0001702265 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,000

Underlying: Common Stock · 114,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.

SEC source: 0001209191-20-061822 · doc4.xml · nonDerivative · entry 2

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

SEC source: 0001209191-20-061822 · doc4.xml · nonDerivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,000

SEC source: 0001209191-21-008108 · doc5.xml · nonDerivative · entry 2

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,383

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-21-008100 · doc5.xml · nonDerivative · entry 2

Wilson Marc · CIK 0001702265 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,191

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-20-049518 · doc4.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-08-31

F1 · derivative.exercise_date: The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to continued service as a director through each such vesting date.

SEC source: 0001209191-20-042897 · doc4.xml · nonDerivative · entry 2

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 1

Disclosed balance after: 890,805

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $14.10 and $15.34 per share. Information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-20-042897 · doc4.xml · nonDerivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 1

Disclosed balance after: 908,305

F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $14.95 and $15.76 per share. Information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-20-038172 · doc4.xml · derivative · entry 1

Kaldor Stephen W · CIK 0001507502 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2030-06-18

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-20-038179 · doc4.xml · derivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2030-06-18

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-20-038166 · doc4.xml · derivative · entry 1

Nichols Weston · CIK 0001746376 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2030-06-18

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-20-038161 · doc4.xml · derivative · entry 1

Okey Stephanie · CIK 0001742616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2020-06-18

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-20-038153 · doc4.xml · derivative · entry 1

WIERENGA WENDALL · CIK 0001235945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2030-06-18

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-21-008120 · doc5.xml · nonDerivative · entry 1

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,516

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-21-008108 · doc5.xml · nonDerivative · entry 1

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,106

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-21-008100 · doc5.xml · nonDerivative · entry 1

Wilson Marc · CIK 0001702265 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,489

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-20-026196 · doc4.xml · derivative · entry 2

WIERENGA WENDALL · CIK 0001235945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 25,329 shares

Expires 2025-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vested monthly thereafter such that all of the shares subject to the option were fully vested as of October 30, 2019.

SEC source: 0001209191-20-026196 · doc4.xml · nonDerivative · entry 1

WIERENGA WENDALL · CIK 0001235945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001213900-20-009500 · ownership.xml · nonDerivative · entry 6

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 298,625

F6 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.3 to $16.3, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

F2 · ownership.nature: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-009500 · ownership.xml · nonDerivative · entry 5

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,162,587

F6 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.3 to $16.3, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

F1 · ownership.nature: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0000899243-20-010940 · doc4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,659,381

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-009500 · ownership.xml · nonDerivative · entry 4

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 308,890

F5 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.0 to $15.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.

F2 · ownership.nature: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-009500 · ownership.xml · nonDerivative · entry 3

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,236,920

F5 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.0 to $15.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-009500 · ownership.xml · nonDerivative · entry 2

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 312,553

F4 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.4 to $16.3, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-009500 · ownership.xml · nonDerivative · entry 1

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,263,447

F4 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.4 to $16.3, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-008792 · ownership.xml · nonDerivative · entry 4

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 338,738

F4 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0 to $15.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-008792 · ownership.xml · nonDerivative · entry 3

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,453,072

F4 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0 to $15.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-008792 · ownership.xml · nonDerivative · entry 2

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 339,480

F2 · ownership.nature: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-008792 · ownership.xml · nonDerivative · entry 1

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,458,445

F1 · ownership.nature: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F3 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-006030 · ownership.xml · nonDerivative · entry 3

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Vivo Opportunity, LLC · CIK 0001728970 · 10% owner

Vivo Opportunity Fund, L.P. · CIK 0001726403 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 168,165

F6 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

F3 · ownership.nature: These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").

F5 · ownership.nature: Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-006030 · ownership.xml · nonDerivative · entry 2

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Vivo Opportunity, LLC · CIK 0001728970 · 10% owner

Vivo Opportunity Fund, L.P. · CIK 0001726403 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 375,880

F6 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

F2 · ownership.nature: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F4 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001213900-20-006030 · ownership.xml · nonDerivative · entry 1

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Vivo Opportunity, LLC · CIK 0001728970 · 10% owner

Vivo Opportunity Fund, L.P. · CIK 0001726403 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,722,045

F6 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

F1 · ownership.nature: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F4 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-012974 · doc4.xml · derivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-02-23

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020.